VisionQuest Biomedical revolutionizes retinal diagnostics with the ASPIRE artificial intelligence (AI) software system to detect malarial retinopathy (MR), a sign of cerebral malaria, a fatal syndrome of malarial disease in Africa that kills hundreds of thousands of children every year. ASPIRE is currently undergoing clinical studies across three countries in Africa. Another product by VisionQuest, EyeStar, provides a market-ready and cost-effective solution to screen for Diabetic Retinopathy (DR), the most common complication of diabetes and the leading cause of blindness among the working-age population. VisionQuest has deployed EyeStar in diabetes clinics to screen for DR in over 40,000 patients to date. VisionQuest is poised to bring EyeStar and ASPIRE to market in the coming years and to deploy its platform of multiple AI technologies in the US and in developing countries.
VisionQuest Biomedical Inc. is presenting as part of the NIH Innovation Zone.